Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab extension study for long-term safety and efficacy
2022-501254-10-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 52
01
Overview
Phase 3, open-label trial of pembrolizumab in Nonhematologic neoplasms and cancer (3 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival. Planned start Aug 2018; status: authorised.
02
Drugs
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2022-501254-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501254-10-00.